Cervical Dystonia Clinical Trial
Official title:
Pre-injection, Multi-channel EMG Mapping to Optimize Botulinum Toxin Type A Efficacy in Cervical Dystonia.
Verified date | March 2020 |
Source | University of California, San Francisco |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine how to improve treatment of patients with cervical dystonia who have not been helped with standard Botox injections. This study is for patients with cervical dystonia who have not benefited from treatment with Botox using conventional "single lead electromyographic (EMG) techniques" for injection. The study aim is to see if these patients may have significantly more benefit if their Botox is injected into muscles that have been chosen with a multi-channel EMG mapping study of the neck prior to Botox injection.
Status | Completed |
Enrollment | 10 |
Est. completion date | January 2011 |
Est. primary completion date | October 2010 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion criteria: - Male or female subjects, 18 to 75 years of age. - Ability to follow study instructions and complete all required visits. - Subject meets diagnostic criteria for idiopathic primary cervical dystonia. - Subject has at least moderate severity Cervical Dystonia, with a baseline rating of at least 30 on the total TWSTRS and at least 15 on the TWSTRS motor severity subsection. - Patients have had a suboptimal response to 2 previous Botulinum toxin injections at an outside facility. - Patients will not have received Botulinum toxin within 16 weeks of the start of the study. - In order to not confound the clinical response to BTX-A injections, all patients enrolled must have been on a stable medication regimen for 30 days. If they are not on medication at the initiation of the study, they will not be started on medication. Patients must be on the same medication regimen through the entire study including assessment of both single lead EMG based injections and "mapping" based injections. Medications cannot be stopped during the study to avoid confounding the clinical response to BTX-A. Exclusion Criteria: - Known allergy or sensitivity to any of the components in BTX-A. - Uncontrolled clinically significant medical condition other than the condition under evaluation - Females with a positive pregnancy test, or who are breast-feeding, planning a pregnancy during the study, who think that they may be pregnant at the start of the study or females of childbearing potential who are unable or unwilling to use a reliable form of contraception during the study. - Participation in another medication or device study or within 3 months of enrollment in this study. - Patients know to have a positive frontalis test or have previously tested positive for the presence of BTX-A antibodies will be excluded. - Any known evidence of cervical contractures or significant spinal deformity. |
Country | Name | City | State |
---|---|---|---|
United States | University of California, San Francisco | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
University of California, San Francisco | Allergan |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pre- and Post-injection Toronto Western Spasmodic Torticollis Rating Scale(TWSTRS): Global Clinical Impression Scale (GCI); Visual Analog Scale(VAS) | pre-injection, week 16, 20, 36, and 40 | ||
Primary | Mean Percentage Change in Total Toronto Western Spasmodic Torticollis Rating Scale | Mean Percentage change in Toronto Western Spasmodic Torticollis Rating Scale. This scale ranges from 0 (normal) to 85 (very severe). | baseline and 48 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03617367 -
Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-OLS)
|
Phase 3 | |
Not yet recruiting |
NCT04057911 -
A Trial of Non-invasive Stimulation in Cervical Dystonia
|
N/A | |
Withdrawn |
NCT02180139 -
tDCS in Cervical Dystonia
|
N/A | |
Completed |
NCT00541905 -
Daily Dystonia Practice - A Trial to Investigate NT 201, the Duration of Treatment Effect After One Injection Session and in Long-term Treatment in Cervical Dystonia
|
Phase 4 | |
Unknown status |
NCT00418925 -
Efficacy of Dronabinol for the Treatment of Cervical Dystonia
|
Phase 2 | |
Not yet recruiting |
NCT05715138 -
Comparison of Pallidal With Subthalamic Deep Brain Stimulation for Cervical Dystonia
|
N/A | |
Completed |
NCT02959645 -
Assessment of Brain Activities in Cervical Dystonia
|
||
Completed |
NCT02131467 -
Safety and Tolerability of Perampanel in Cervical Dystonia
|
Phase 1/Phase 2 | |
Completed |
NCT03805152 -
Abobotulinum Toxin and Neubotulinum Toxin Injection in Cerivical Dystonia
|
Phase 3 | |
Completed |
NCT04949594 -
Relief of Pain in Patients With Cervical Dystonia Through the Use of Transcutaneous Electric Nerve Stimulation (TENS)
|
||
Recruiting |
NCT01664013 -
The Impact of Botulinum Toxin Treatment in Quality of Life of Cervical Dystonia Patients
|
Phase 4 | |
Completed |
NCT00447772 -
Study to Assess the Efficacy and Safety of Dysport® in Cervical Dystonia
|
Phase 3 | |
Completed |
NCT00210431 -
Post Marketing Surveillance Study of Dysport
|
||
Completed |
NCT05157100 -
Clinical Study of Ingrezza (Valbenazine) for the Treatment of Cervical Dystonia
|
Phase 4 | |
Completed |
NCT00257660 -
Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
|
Phase 3 | |
Completed |
NCT05103202 -
Efficacy and Safety of 10-Week or Shorter vs 12-Week or Longer Injection Intervals of Botulinum Toxin
|
||
Terminated |
NCT00760318 -
Keppra for Cervical Dystonia
|
Phase 2 | |
Completed |
NCT00323765 -
Plasticity in Cervical Dystonia
|
N/A | |
Completed |
NCT04171258 -
Clinical Trial to Compare the Safety and Efficacy of Botulax® Versus Botox® in Patients With Cervical Dystonia
|
Phase 1 | |
Completed |
NCT04849988 -
A Phase 2 Study to Evaluate the Safety and Efficacy of ABP-450 in the Treatment of Cervical Dystonia
|
Phase 2 |